Augmentation of superoxide levels has been linked to impaired relaxation in hypertension, diabetes and hypercholesterolaemia. Purified endothelial nitric oxide synthase (eNOS) generates superoxide under limited availability of 5,6,7,8-tetrahydrobiopterin (BH % ). Thus alterations in endothelial BH % levels have been postulated to stimulate superoxide production from eNOS. This possibility was examined by determining the concentrationdependent effects of BH % , and its analogues, on superoxide formation by eNOS. Superoxide was quantified by EPR spin trapping, which is the only available technique to quantify superoxide from eNOS. Using 5-ethoxycarbonyl-5-methyl-pyrroline N-oxide, we show that only fully reduced BH % diminished superoxide release from eNOS, with efficiency BH % 6-methyl-BH % 5-methyl-BH % . In contrast, partially oxidized BH % analogues, 7,8-dihydrobiopterin (7,8-BH # ) and sepiapterin had no
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INTRODUCTION
Vasorelaxation is elicited by dNO [1, 2] derived from endothelial cells in response to agonist-mediated activation of endothelial nitric oxide synthase (eNOS). This enzyme catalyses the oxidation of -arginine to generate -citrulline and dNO upon activation with calcium\calmodulin. dNO diffused from endothelial cells to vascular smooth muscle cells enhances cGMP levels and regulates intracellular calcium ion concentrations required for vasorelaxation. Thus there exist several checkpoints in the dNO-cGMP pathway that can modulate dNO-dependent vasorelaxation. Loss of endothelial-dependent vasorelaxation (endothelial dysfunction) occurs from decreased basal concentrations of dNO [3, 4] . The mechanisms modulating dNO concentration in the vascular wall, however, are not fully understood. Regulation of the dNO-cGMP pathway in i o may be attributed to either impaired formation of dNO and\or increased reaction with superoxide [5, 6] . Increased formation of superoxide anion has been linked to the pathogenesis of chronic vascular diseases, such as atherosclerosis, diabetes and hypertension [7] [8] [9] . Endothelial dysfunction associated with these conditions has been attributed to the rapid reaction between superoxide and dNO generating peroxynitrite, a potent oxidant [10] that can induce endothelial damage [11, 12] . 5,6,7,8-Tetrahydrobiopterin (BH % ), an essential cofactor in dNO biosynthesis, has been shown to improve endotheliumdependent vasodilation in patients with coronary artery disease [13] , type II diabetes mellitus [14] , smokers [15, 16] 1 To whom correspondence should be addressed (e-mail jvvivar!mcw.edu).
effect. Neither -arginine nor N G -nitro--arginine methyl ester (-NAME) abolished superoxide formation. Together, BH % and -arginine stimulated dNO production at maximal rates of 148 nmol\min per mg of protein. These results indicate that BH % acts as a ' redox switch ', decreasing superoxide release and enhancing dNO formation. This role was verified by adding 7,8-BH # or sepiapterin to fully active eNOS. Both 7,8-BH # and sepiapterin enhanced superoxide release while inhibiting dNO formation. Collectively, these results indicate that the ratio between oxidized and reduced BH % metabolites tightly regulates superoxide formation from eNOS. The pathological significance of this scenario is discussed.
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[17] and several other disease models [18, 19] . BH % deficiency reportedly impairs dNO-dependent vasodilation. How intracellular BH % concentrations modulate the dNO-cGMP pathway is an area of active investigation. Scavenging of superoxide by BH % was suggested to be a mechanism by which BH % enhances dNO concentrations. We recently determined the rate constant for the reaction between BH % and superoxide to be approx. 10& M −" : s −" . Our results indicate that BH % reacts with superoxide at rates very close to that of ascorbate [20] . However, BH % mediates vasorelaxation at much lower concentrations than ascorbate [21] . Thus it is likely that BH % acts through mechanisms other than superoxide scavenging.
Previously, we showed that BH % decreases the formation of superoxide from the oxygenase domain of NOS [22, 23] . This suggested that BH % , by controlling superoxide generation from eNOS, is important for modulating the dNO-cGMP pathway. In the present study, we examined the mechanisms by which BH % and its analogues ( Figure 1 ) inhibit superoxide release from BH % -free eNOS. We demonstrated that BH % , but not -arginine or -arginine analogues, such as N G -nitro--arginine methyl ester (-NAME) or N G -monomethyl--arginine (-NMMA), completely abolishes superoxide release from eNOS. Unlike BH % , the oxidized BH % analogues 7,8-dihydrobiopterin (7,8-BH # ) and sepiapterin augment superoxide release from eNOS even in the presence of -arginine. Both 7,8-BH # and sepiapterin were shown to antagonize the effects of BH % and inhibit dNO formation. Based on these results, we conclude that the ratio between reduced and oxidized BH % metabolites tightly controls superoxide Figure 1 Chemical structures of natural and synthetic pteridines formation from eNOS. This mechanism suggests that oxidantinduced alterations in intracellular BH % levels and\or decreased BH % formation play a key role in the aetiology of endothelial dysfunction associated with conditions such as hypertension, hypercholesterolaemia, diabetes and atherosclerosis [7] [8] [9] . and -arginine, NADPH, calcium chloride, GSH, imidazole and BSA were obtained from Sigma. Haemoglobin was purchased from Calbiochem, and diethylenetriaminepenta-acetic acid (DTPA) was obtained from Fluka Chemika-BioChemika. 5-Ethoxycarbonyl-5-methyl-pyrroline N-oxide (EMPO) was synthesized as previously described [24] , and kept at k80 mC until used. Recombinant wild-type eNOS was purified in the absence of BH % as previously described [22] , and its protein concentration was determined, based on haem content, by reduced carbon monoxide difference spectra using an absorption coefficient of 100 mM −" : cm −" for an absorbance difference between 444 and 475 nm. The average haem content of the protein was 85 %. Three different protein batches that had an enzyme activity ranging from 180 to 100 nmol of -["%C]citrulline\min per mg of protein were used in the present study.
EXPERIMENTAL Materials
(6R)-BH % ,(6S)
EPR measurements
EPR measurements were recorded at approx. 25 mC on a Varian E-109 spectrometer operating at 9.01 GHz and 100 kHz field modulation equipped with a loop gap resonator [25] . This cavity enables the analysis of a sample volume of 10 µl. Reactions (20 µl, final volume) were initiated by the addition of enzyme, BH % -free eNOS or xanthine oxidase, to incubation mixtures containing 50 mM EMPO spin trap. EPR spectra were scanned for 100 G (x-axis) with a signal ( y-axis) receiver gain of 5i10%. The concentration of superoxide adduct was calculated by double integration of the simulated spectra, using EPR software by D. R. Duling [26] . 3-Carbamoyl-2,2,5,5,-tetrametlypyrrolidine N-oxyl was used as a standard.
Biochemical assays eNOS activity
Enzyme activity was determined by either quantifying the conversion of -["%C]arginine into -["%C]citrulline as previously described [20] , or by the haemoglobin assay. Briefly, eNOS was added to a reaction mixture containing NADPH (0.1 mM), -arginine (40 µM), calcium (0.2 mM), calmodulin (20 µg\ml), GSH (0.1 mM), BSA (0.1 mg\ml), BH % (10 µM, unless otherwise specified), DTPA (0.1 mM), oxy-haemoglobin (approx. 8 µM) and Hepes (50 mM, pH 7.4). Oxidation of oxy-haemoglobin was followed at 401 nm for 1 min at approx. 25 mC and dNO formation was calculated using an absorption coefficient of 38 mM −" : cm −" .
NADPH consumption
Initial rates of NADPH oxidation by eNOS were determined at 340 nm. NADPH concentrations were calculated using an absorption coefficient of 6.22 mM −" : cm −" . Reactions were initiated by adding NADPH (approx. 0.18 mM) to reaction mixtures (final volume, 0.25 ml) containing eNOS (approx. 2.5 µg), DTPA (0.1 mM), calcium (0.2 mM), calmodulin (20 µg\ml) and other additions in Hepes buffer (50 mM, pH 7.4)
RESULTS

Only fully reduced BH 4 inhibits superoxide release from eNOS
Figure 2(A) shows the EMPO-superoxide adduct (EMPO-OOH) detected upon activation of BH % -free eNOS with calcium\ calmodulin. This result is consistent with our previous data using the phosphorylated spin trap 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide (' DEPMPO ') [21] . In the present study we used EMPO because it produces a more simple EPR spectrum, facilitating superoxide quantification [24, 27] . Formation of EMPO-OOH from eNOS was inhibitable by 1 mM cyanide (results not shown). This further corroborates our previous findings, which indicate that superoxide is released from the haem group in the oxygenase domain of the enzyme [22] .
An important role of BH % in the catalytic cycle of NOS is to control haem reactivity [28, 29] . To examine how pteridines (Figure 1 ) affect the release of superoxide from the haem group in eNOS, BH % -free enzyme was reconstituted with BH % and synthetic BH % analogues, such as 6Me-BH % and 5Me-BH % . The activity of these reduced pteridines on superoxide release was compared with partially oxidized BH % analogues, such as 7,8-BH # and sepiapterin. As shown in Figure 2 , 7,8-BH # ( Figure 2B ) and sepiapterin (results not shown) did not diminish superoxide from eNOS. By contrast, 5Me-BH % ( Figure 2C ), 6Me-BH % ( Figure 2D ) and BH % ( Figure 2E ) significantly diminished superoxide in a concentration-dependent fashion. At a concentration of 10 µM, 5Me-BH % inhibited superoxide by approx. 7 % (results not shown), whereas inhibition by 6Me-BH % was approx. 80 %, and BH % completely abolished superoxide formation. These results demonstrate that only fully reduced pteridines inhibit superoxide release from eNOS and suggest that the affinity of the pteridine for the eNOS binding 
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Figure 3 Effect of BH 4 diastereomers and 7,8-BH 2 on the formation of dNO by eNOS
Pterin-free eNOS (2.6 µg) was incubated in the presence of () (6R )-BH 4 , ($) (6S )-BH 4 or (>) 7,8-BH 2 at the indicated concentrations. Formation of dNO was measured by the haemoglobin assay as described in the Experimental section. Data represent the means of at least two independent experiments using different enzyme batches.
Figure 4 BH 4 -dependent superoxide and dNO formation from eNOS
Superoxide formation ( ; left-hand axis) was quantified with EMPO (50 mM) added to eNOS incubation mixtures containing calcium (0.2 mM), calmodulin (20 µg/ml), NADPH (0.1 mM), DTPA (0.1 mM) and (6R )-BH 4 at the indicated concentrations in Hepes buffer (50 mM, pH 7.4), in a final volume of 20 µl, at approx. 25 mC. Rates of EMPO-OOH formation were determined as described in the Experimental section. dNO ($ ; right-hand axis) and L-citrulline (# ; righthand axis) were measured upon addition of L-arginine (0.1 mM) to identical eNOS incubations used in the superoxide measurements as described in the Experimental section.
site determines the efficiency with which these analogues inhibit superoxide.
To characterize the role of pteridine binding in the regulation of both superoxide and dNO generation from eNOS, the effects of (6R)-and (6S)-BH % diastereomers were examined. As shown in Figure 3 , (6R)-BH % maximally stimulated eNOS to generate 145.2p4.1 nmol of dNO\min per mg of protein, whereas its diastereomer, (6S)-BH % , supported only 75 % of the maximal activity even when added at concentrations approx. 30-fold higher than eNOS. Parallel experiments demonstrated that a 2-fold higher concentration of (6S)-BH % was necessary to diminish superoxide at a similar level to (6R)-BH % (results not shown). These results demonstrate that (6R)-BH % specifically inhibits superoxide release from eNOS with an efficiency that correlates with its high affinity for the enzyme. In addition, these results suggest that there is a strong association between the potency of inhibition of superoxide and stimulation of dNO formation. This relationship was further confirmed with 5Me-BH % , which did not efficiently inhibit superoxide release from eNOS. Accordingly, 5Me-BH % (10 µM) stimulated only 20 % of the maximal rates of dNO formation obtained with BH % (10 µM). Higher 5Me-BH % concentrations (100 µM) were necessary to reach 80 % of the maximal activity.
The quantitative relationship between superoxide, dNO formation and BH % was examined in parallel incubations. Rates of superoxide formation were quantified by measuring EMPO-OOH. Activation of -arginine and BH % -free eNOS with calcium\calmodulin in the presence of EMPO generated 11.8 nmol of EMPO-OOH\min per mg of protein. This was equivalent to the rate of EMPO-OOH formation by a xanthine\xanthine oxidase system producing 0.126 nmol of superoxide\min. BH % -free eNOS was subsequently shown to generate 97.7 nmol of superoxide\min per mg of protein at approx. 25 mC. Reconstitution of eNOS with BH % diminished superoxide formation, with an IC &! of approx. 0.14 µM ; at a concentration 10 times higher, BH % abolished superoxide formation (Figure 4 ). In the presence of -arginine, BH % stimulated the formation of dNO with a half- maximal effective dose of approx. 0.25 µM ; maximal rates of dNO formation were attained at BH % concentrations of 10 µM. This result suggested that BH % inhibits superoxide formation from eNOS more efficiently than it stimulates dNO formation. Since detection of dNO by the haemoglobin assay can be underestimated under conditions where both dNO and superoxide are generated, we investigated the effect of BH % on eNOS activity by following -["%C]citrulline formation. Essentially the same pattern observed for dNO formation (Figure 4 ) was obtained when -["%C]citrulline was quantified (Figure 4) , indicating that the concomitant formation of dNO and superoxide by eNOS is unlikely.
L-Arginine and its analogues do not prevent superoxide release from eNOS
Spin trapping experiments demonstrated that -arginine did not inhibit superoxide release from BH % -free eNOS ( Figure 5A ). By contrast, formation of superoxide was enhanced by approx. 60 % when the enzyme was incubated with -arginine prior to activation with calcium\calmodulin ( Figure 5B ). In combination with 7,8-BH # ( Figure 5C ) or sepiapterin (results not shown), -arginine stimulated superoxide formation to the same extent as in the absence of the pteridines ( Figure 5B) . Previous results by others showed that -arginine enhances uncoupled oxidation of NADPH [29] . Thus it is likely that -arginine binding facilitates iron haem reduction that facilitates oxygen activation and superoxide formation. In the presence of BH % , the process results in increased oxidation of -arginine to dNO and -citrulline, thereby preventing superoxide formation ( Figure 5D ).
To understand whether occupation of the -arginine binding site controls the rate of electron transfer from the reductase domain to the haem group, we examined the effects of -arginine analogues on the rate of NADPH consumption. -NAME and -NMMA are competitive eNOS inhibitors that have a high affinity for eNOS (IC &! l 0.5-0.7 µM). As shown in Table 1 , -NAME inhibited NADPH consumption in a concentrationdependent manner, reaching a maximum of approx. 32 % inhibition at approx. 1 mM concentration. -NMMA had a Oxidized BH 4 and L-arginine augment superoxide release from eNOS marginal effect on the rates of NADPH consumption at all the concentrations tested (0.1-1 mM). These results suggest that occupation of the -arginine binding site does not enhance NADPH oxidation and consequently superoxide formation from eNOS. Alternatively, this finding suggested that modifications in the iron spin state control the rates of haem reduction. This was verified with imidazole and 7-nitroindazole (IC &! values of approx. 0.8 µM), two NOS inhibitors that bind to the iron haem group blocking its reactivity [30] . Both inhibitors efficiently diminished NADPH oxidation ( 50 % at 0.1 mM ; Table 1 ). These results demonstrate that -arginine enhances NADPH oxidation by facilitating haem reduction and thereby oxygen binding. Identical experiments using BH % -replenished enzyme were performed to examine how BH % modifies NADPH consumption in the presence of -arginine analogues. As shown in Table 1 , addition of BH % did not greatly affect NADPH oxidation under any of the tested conditions.
In contrast with the results described above, we have shown that -arginine and its analogues inhibit superoxide release from the neuronal isoform of NOS [21] . To investigate whether the inhibitory effects of -arginine analogues on superoxide release from eNOS were more discrete than with the neuronal isoform of
Figure 8 7,8-BH 2 enhances superoxide and inhibits dNO formation from eNOS
Superoxide ( , right-hand axis) was quantified with EMPO (50 mM) added to eNOS incubation mixtures containing BH 4 (2 µM), L-arginine (0.1 mM), NADPH (0.1 mM), calcium (0.2 mM), calmodulin (20 µg/ml), DTPA (0.1 mM), Hepes (50 mM, pH 7.4) and 7,8-BH 2 at the indicated concentrations. Rates of EMPO-OOH formation were calculated as described in the Experimental section. Rates of dNO formation ($, left-hand axis) were determined using the haemoglobin assay as described in the Experimental section.
NOS, superoxide measurements were performed using ["&N]-EMPO [27] . This labelled spin trap enhances the sensitivity of the assay by producing a four-line EPR spectrum of the ["&N]EMPO superoxide adduct (["&N]EMPO-OOH), compared with the six lines of ["%N]EMPO-OOH. As shown in Figure 6 , -NAME (1 mM) inhibited ["&N]EMPO-OOH by only 20 %, whereas imidazole (0.1 mM) inhibited ["&N]EMPO-OOH by approx. 65 %. These results indicate that -NAME is not an efficient inhibitor of haem iron reduction and superoxide release from eNOS. Also, these results demonstrate that the effects of -arginine and -arginine analogues on the control of superoxide release depend on the particular isoform of NOS.
Oxidized BH 4 analogues stimulate superoxide production from eNOS
Dihydrobiopterins, such as 7,8-BH # and sepiapterin, bind to eNOS [31] , emulating several of the allosteric and electronic effects of BH % , but they do not support dNO formation [32] . Thus we anticipated that displacement of BH % from eNOS by its analogues would increase superoxide formation. To examine this possibility, minimal amounts of BH % were used to ensure that free BH % concentrations were kept at a minimum while stimulating dNO formation at rates close to the V max . From the experiments in Figure 4 , it was determined that this condition was attained with 2 µM BH % , which supported 97 % dNO synthesis with no superoxide formation ( Figure 7A ). Supplementation with 7,8-BH # and sepiapterin, however, caused a robust increase in superoxide formation (Figures 7B-7D ). This result indicates that 7,8-BH # and sepiapterin compete with BH % for the same binding site in eNOS that inhibits dNO and enhances superoxide formation. As shown in Figure 8, 
